Soleno Therapeutics Files 8-K on Security Holder Vote Matters
Ticker: SLNO · Form: 8-K · Filed: 2024-06-06T00:00:00.000Z
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
Related Tickers: SLNO
TL;DR
SOLENO THERAPEUTICS (SLNO) is having a shareholder vote on June 6th. Big decisions ahead.
AI Summary
On June 6, 2024, Soleno Therapeutics, Inc. filed an 8-K report detailing a submission of matters to a vote of security holders. The company, formerly known as Capnia, Inc., is incorporated in Delaware and headquartered in Redwood City, California.
Why It Matters
This filing indicates that Soleno Therapeutics is engaging its security holders on important corporate decisions, which could impact the company's future direction and shareholder value.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of a shareholder vote, not indicating any immediate financial distress or significant operational change.
Key Players & Entities
- SOLENO THERAPEUTICS, INC. (company) — Registrant
- Capnia, Inc. (company) — Former company name
- June 6, 2024 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- Redwood City, CA (location) — Principal executive offices
FAQ
What specific matters are being submitted to a vote of security holders?
The filing states that it is a 'Submission of Matters to a Vote of Security Holders' but does not specify the exact proposals in the provided text.
When was Soleno Therapeutics, Inc. formerly known as Capnia, Inc.?
The date of the name change from Capnia, Inc. to Soleno Therapeutics, Inc. was February 19, 2010.
What is Soleno Therapeutics' state of incorporation?
Soleno Therapeutics, Inc. is incorporated in Delaware.
Where are Soleno Therapeutics' principal executive offices located?
The principal executive offices are located at 203 Redwood Shores Parkway, Suite 500, Redwood City, CA 94065.
What is the SEC file number for Soleno Therapeutics?
The SEC file number for Soleno Therapeutics is 001-36593.
Filing Stats: 658 words · 3 min read · ~2 pages · Grade level 12.8 · Accepted 2024-06-06 16:29:59
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value SLNO NASDAQ Indicate by
Filing Documents
- d834951d8k.htm (8-K) — 33KB
- d834951dex101.htm (EX-10.1) — 85KB
- 0001193125-24-156113.txt ( ) — 260KB
- slno-20240606.xsd (EX-101.SCH) — 3KB
- slno-20240606_lab.xml (EX-101.LAB) — 18KB
- slno-20240606_pre.xml (EX-101.PRE) — 11KB
- d834951d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SOLENO THERAPEUTICS, INC. Date: June 6, 2024 By: /s/ Anish Bhatnagar Anish Bhatnagar Chief Executive Officer